TNF and Alzheimer disease: Importantly, a recent large epidemiological study, in which administering regular subcutaneous etanercept, a specific anti-TNF biological agent in common clinical use, over an extended period in treatment of rheumatoid arthritis (RA), was reported to reduce incidence of AD [123] in these patients.